Home / Market News / $STXS

$STXS news and market catalysts

The 8 most recent market catalysts affecting $STXS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

8 catalysts 0 high impact 4 bullish 2 bearish Medical Devices
Nov 11, 2026 Corporate Catalyst Bullish Impact 75
Stereotaxis Announces Convertible Note Financing of Up To $24 Million
Stereotaxis announced a convertible note financing agreement for up to $24 million, with an immediate $12 million infusion and another $12 million contingent on regulatory mileston…
Nov 11, 2026 Corporate Catalyst Neutral Impact 75
Stereotaxis Reports Third Quarter 2026 Financial Results
Stereotaxis reported a robust third quarter for 2026, with overall revenue up 20% and system revenue showing an impressive 58% increase. This indicates strong demand for their robo…
Nov 2, 2026 Corporate Catalyst Bullish Impact 65
Stereotaxis Announces First-in-Human Clinical Results for Robocath's Next-Generation Robotic System
Stereotaxis announced that Robocath's next-generation robotic system, for which Stereotaxis is a partner or distributor, achieved a 100% clinical success rate in its first-in-human…
Oct 31, 2026 Corporate Catalyst Bullish Impact 65
Canon Medical and Stereotaxis Announce Technology Compatibility and Commercial Collaboration
Stereotaxis and Canon Medical Systems USA have announced a technology compatibility and commercial collaboration. This partnership is significant as it aims to integrate Stereotaxi…
Aug 31, 2026 Corporate Catalyst Bullish Impact 75
Stereotaxis Secures FDA 510(k) Clearance For GenesisX Robotic Magnetic Navigation System
Stereotaxis has secured FDA 510(k) clearance for its GenesisX Robotic Magnetic Navigation System, which is an upgrade to its current Genesis RMN system. This regulatory approval is…
Aug 27, 2026 Corporate Catalyst Bearish Impact 55
Citizens Maintains Market Outperform on Stereotaxis, Lowers Price Target to $3
Citizens analyst Daniel Stauder reiterated a 'Market Outperform' rating for Stereotaxis (STXS) but simultaneously lowered the stock's price target from $4 to $3. This action signal…
Aug 11, 2026 Corporate Catalyst Bearish Impact 75
Stereotaxis Q2 EPS $(0.05) Beats $(0.06) Estimate, Sales $7.670M Miss $8.350M Estimate
Stereotaxis (STXS) announced its Q2 earnings, revealing a beat on EPS but a notable miss on revenue. The company's sales of $7.670 million fell short of the $8.350 million estimate…
Jul 15, 2026 Corporate Catalyst Neutral Impact 65
Stereotaxis Files Prospectus Related To Resale Of 108.87M Shares Of Common Stock By Selling Stockholders
Stereotaxis has filed a prospectus to register 108.87 million shares of common stock for resale by existing selling stockholders. This is not a primary offering by Stereotaxis to r…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.